Last reviewed · How we verify
Anti-hypertensive therapy
At a glance
| Generic name | Anti-hypertensive therapy |
|---|---|
| Also known as | Normodyne, Trandate, Procardia XL, Adalat |
| Sponsor | University of Alabama at Birmingham |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Nutritional Ketosis Marfan (NA)
- BradycArdia paCemaKer With AV Interval Modulation for Blood prEssure treAtmenT (NA)
- REnin-guided TherApy With MinEralocorticoid Receptor Antagonists in Primary Aldosteronism - Feasibility Study (NA)
- Unknown Time of Onset Stroke RePerfusIon Without Advanced Imaging (PHASE3)
- Intravenous Tenecteplase in Very Old Patients With Acute Ischemic Stroke
- Efficacy and Safety of IBI362 in Hypertensive Patients With Overweight/Obesity (PHASE3)
- Postpartum Preeclampsia Early Detection and Treatment: Nepal Pilot Study (NA)
- The Effect of Pharmacist-Initiated Home Blood Pressure Monitoring on Blood Pressure Control in Women (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Anti-hypertensive therapy CI brief — competitive landscape report
- Anti-hypertensive therapy updates RSS · CI watch RSS
- University of Alabama at Birmingham portfolio CI